Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VIR with free AI briefings, catalyst countdowns, and dilution alerts.

VIR · Vir Biotechnology, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$454.6M Cash on Hand
CF+ Cash Runway
Follow VIR by email Get an email when VIR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VIR, unsubscribe in one click. Privacy

📣 What VIR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Cilgavimab/Tixagevimab (AZD7442) Covid19 Phase 3 · NCT04501978 Completed
Sotrovimab (VIR-7831) Covid19 Phase 2/3 · NCT04545060 Completed
Tobevibart Viral Hepatitis Phase 3 · NCT07128550 Active not recruiting
Lufotrelvir Covid19 Phase 3 · NCT04501978 Completed
Ensovibep (MP0420) Covid19 Phase 3 · NCT04501978 Completed
Bamlanivimab (LY3819253) Covid19 Phase 3 · NCT04501978 Completed
Elebsiran Viral Hepatitis Phase 3 · NCT07128550 Active not recruiting
Amubarvimab (BRII-196) Covid19 Phase 3 · NCT04501978 Completed
VIR-5818 Locally Advanced or Metastatic HER2-Expressing Cancers Phase 1/2 · NCT05356741 Recruiting
VIR-2482 Influenza A Phase 2 · NCT05567783 Terminated
Bebtelovimab COVID-19 Phase 2 · NCT04634409 Completed
Tenofovir Alafenamide Chronic Hepatitis B Phase 2 · NCT04891770 Completed
Tenofovir Disoproxil Fumarate Hepatitis B, Chronic Phase 1/2 · NCT05612581 Completed
BRII-179 For Treatment of Chronic Hepatitis B Virus Infection Phase 2 · NCT06491563 Completed
Selgantolimod Chronic Hepatitis B Phase 2 · NCT04891770 Completed
Interferon Hepatitis B, Chronic Phase 2 · NCT04749368 Completed

Also used in these trials (approved or third-party drugs, not VIR's own candidates): Remdesivir, Bulevirtide, Pembrolizumab, Nivolumab, Docetaxel Anhydrous.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VIR holds $454.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 7 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VIR files for a raise →

👥 Who Owns VIR

Insiders 10% Other 5%+ holders 13.7% Institutions (358 holders) 76.3% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 20,905,681 12.21% 2026-09-30
SVF Endurance (Cayman) Ltd
10% owner
Insider 13,728,924 8.02% 2025-12-01
Robert Nelsen 5%+ holder (13D) 12,508,029 7.30% 2026-11-04
Vanguard Portfolio Management Institution (13G, 5%+) 11,554,377 6.75% 2026-06-30
SB Investment Advisers (UK) Limited 5%+ holder (13G) 10,948,093 6.39% 2026-03-31
Vicki L Sato
Director
Insider 1,078,391 0.63% 2026-05-01
Backer Marianne De
President and CEO, Director · +570,000 options
Insider 1,001,263 0.58% 2026-04-29
Robert J More
Director · +16,000 options
Insider 558,573 0.33% 2026-08-11
Jason O'Byrne
EVP & Chief Financial Officer · +110,000 options
Insider 162,615 0.09% 2026-03-20
Mark Eisner
EVP and Chief Medical Officer · +110,000 options
Insider 154,024 0.09% 2026-02-24
Brent Sabatini
SVP, Chief Accounting Officer · +50,000 options
Insider 111,902 0.07% 2026-11-15
Verneuil Vanina de
EVP, General Counsel, Corp Sec · +110,000 options
Insider 110,193 0.06% 2026-11-02

Share count 171,270,773 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full VIR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VIR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.